Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium longum + lactobacillus acidophilus + enterococcus faecalis (Shanghai New Asiatic Pharmaceutical)
- Development stage
- Unknown
- Lead developer
- Shanghai New Asiatic Pharmaceutical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium triplex live bacteria capsule is a live biotherapeutic product widely used in China for the treatment of intestinal dysbiosis and as an adjunct therapy for *Helicobacter pylori* eradication. It typically contains three live bacterial strains: *Bifidobacterium longum*, *Lactobacillus acidophilus*, and *Enterococcus faecalis*. The mechanism involves restoring the balance of the intestinal microbiota, inhibiting the growth of pathogenic bacteria through competitive exclusion and the production of organic acids, and modulating the host immune response. In clinical practice, it is frequently added to standard quadruple therapy for *H. pylori* to improve eradication rates and mitigate gastrointestinal side effects associated with antibiotic use.
- Brand names
- PeifeikangBifid
- Other names
- Bifidobacterium Triple Viable CapsulesBifidobacterium triplex live bacteria capsule双歧杆菌三联活菌胶囊
Beyond the preview
Go deeper on bifidobacterium longum + lactobacillus acidophilus + enterococcus faecalis (Shanghai New Asiatic Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium longum + lactobacillus acidophilus + enterococcus faecalis (Shanghai New Asiatic Pharmaceutical).